View in EDS HTML Full Text PDF Full Text

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.

Saved in:
Bibliographic Details
Title: Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.
Authors: Gaudian K; Washington University School of Medicine in St. Louis, St. Louis, MO, United States., Koh MJ; School of Medicine, Georgetown University, Washington, DC, United States., Koh MJ; School of Medicine, Georgetown University, Washington, DC, United States., Collins RR; College of William and Mary, Williamsburg, VA, United States., Eden S; Systems Medicine Program, Georgetown University Medical Center, Washington, DC, United States., Zwart Z; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Danner M; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States., Zwart A; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Fallick M; Novartis, US Medical Affairs, Oncology, East Hanover, NJ, United States., Kumar D; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States., Leger P; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Dawson NA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Suy S; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States., Collins SP; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States.
Source: Frontiers in oncology [Front Oncol] 2025 Jan 30; Vol. 15, pp. 1540482. Date of Electronic Publication: 2025 Jan 30 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39949742
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gaudian+K%22">Gaudian K</searchLink>; Washington University School of Medicine in St. Louis, St. Louis, MO, United States.<br /><searchLink fieldCode="AU" term="%22Koh+MJ%22">Koh MJ</searchLink>; School of Medicine, Georgetown University, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Koh+MJ%22">Koh MJ</searchLink>; School of Medicine, Georgetown University, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Collins+RR%22">Collins RR</searchLink>; College of William and Mary, Williamsburg, VA, United States.<br /><searchLink fieldCode="AU" term="%22Eden+S%22">Eden S</searchLink>; Systems Medicine Program, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Zwart+Z%22">Zwart Z</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Danner+M%22">Danner M</searchLink>; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States.<br /><searchLink fieldCode="AU" term="%22Zwart+A%22">Zwart A</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Fallick+M%22">Fallick M</searchLink>; Novartis, US Medical Affairs, Oncology, East Hanover, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Kumar+D%22">Kumar D</searchLink>; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States.<br /><searchLink fieldCode="AU" term="%22Leger+P%22">Leger P</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Dawson+NA%22">Dawson NA</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Suy+S%22">Suy S</searchLink>; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States.<br /><searchLink fieldCode="AU" term="%22Collins+SP%22">Collins SP</searchLink>; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Jan 30; Vol. 15, pp. 1540482. <i>Date of Electronic Publication: </i>2025 Jan 30 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39949742
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1540482
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1540482
    Titles:
      – TitleFull: Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gaudian K
      – PersonEntity:
          Name:
            NameFull: Koh MJ
      – PersonEntity:
          Name:
            NameFull: Koh MJ
      – PersonEntity:
          Name:
            NameFull: Collins RR
      – PersonEntity:
          Name:
            NameFull: Eden S
      – PersonEntity:
          Name:
            NameFull: Zwart Z
      – PersonEntity:
          Name:
            NameFull: Danner M
      – PersonEntity:
          Name:
            NameFull: Zwart A
      – PersonEntity:
          Name:
            NameFull: Fallick M
      – PersonEntity:
          Name:
            NameFull: Kumar D
      – PersonEntity:
          Name:
            NameFull: Leger P
      – PersonEntity:
          Name:
            NameFull: Dawson NA
      – PersonEntity:
          Name:
            NameFull: Suy S
      – PersonEntity:
          Name:
            NameFull: Collins SP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 01
              Text: 2025 Jan 30
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1